

5 June 2024

Extension of Secured Notes

Melodiol Global Health Limited (ASX:ME1) ('Melodiol' or 'the Company') is pleased to advise that has reached an agreement with the Briant Nominees for the extension of its secured notes with the Company (refer to announcements dated 1 November 2022 and 26 October 2023 for additional background information).

Under the terms of the extension, the maturity of the notes will be extended to allow for the following repayment timeline:

- \$250,000 of principal paid either in cash or through the Company sourcing a new investor for assignment of \$250,000 of the loans by 31 May 2024
- \$200,000 of principal paid either in cash or through the Company sourcing a new investor for assignment of \$200,000 of the loans by 30 June 2024
- Two thirds of the remaining principal and accrued interest and other fees payable by 15 August 2024, with 50% payable in cash and 50% payable in shares based on a 20% discount to the 10-day VWAP at the time of conversion into shares
- One third of the remaining principal and accrued interest and other fees payable by 30 September 2024, with 50% payable in cash and 50% payable in shares based on a 20% discount to the 10-day VWAP at the time of conversion into shares
- An extension fee equal to 20% of the face value of the loans and accrued interest as of 1 May 2024
 - o Extension fees to be paid within the 15 August 2024 and 30 September 2024 payments

Share based payments are subject to shareholder approval, and the Company received shareholder approval at its annual general meeting on 31 May 2024 for these issuances (refer to the Company's notice of meeting dated 2 May 2024 for additional information on the share based repayments). The Company has also entered into a side letter to ensure that any share based payments are sold by the Briant Nominees in an orderly manner, such that no more than 25% of the daily trading volume may be sold in a single day. In exchange for the trading restrictions, the Company has agreed to compensate the Briant Nominees for any shortfall in realized amounts, either via a cash payment or settlement in shares. Any share based payments would have a floor price based on a post-consolidation price of \$0.0015. The Company notes that the 31 May 2024 payments have not been made yet, but are expected to be made during the week of 3 June 2024 and that the lenders are aware of this.

-Ends-

Authority and Contact Details

This announcement has been authorised for release by the CEO and MD of Melodiol Global Health Limited.

For further information, please contact:

Investor Enquiries

Melodiol Global Health Limited

E: info@cresopharma.com

P: +61 (0) 497 571 532

About Melodiol

Melodiol Global Health Limited (ASX:ME1) brings the best of cannabis and other plant-based products to better the lives of people and animals. Melodiol strives for the highest quality in its products. It develops cannabis, hemp-derived and other plant based therapeutic, nutraceutical, and lifestyle products with wide consumer reach.

To learn more please visit: <https://melodiolglobalhealth.com/>

Melodiol offices:

Australia: Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

Canada: 59 Payzant Drive, Windsor, Nova Scotia, B0N 2T0 and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2T0

Forward Looking statements

This announcement contains forward-looking statements with respect to Melodiol and its respective operations, strategy, investments, financial performance and condition.

These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Melodiol could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Melodiol and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Melodiol has no obligation to up-date such statements, except to the extent required by applicable laws.